Susquehanna International Group
CNTX icon

Susquehanna International Group’s Context Therapeutics CNTX Stock Holding History

Susquehanna International Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.87M Buy
+1,093,894
New +$2.55M ﹤0.01% 5358
2025
Q4 		– Sell
-21,967
Closed -$21.3K – 12503
2025
Q3 		$21.3K Buy
+21,967
New +$17.8K ﹤0.01% 12043
2025
Q1 		– Sell
-10,185
Closed -$10.7K – 12583
2024
Q4 		$10.7K Sell
10,185
-44,026
-81% -$76.2K ﹤0.01% 11979
2024
Q3 		$106K Buy
+54,211
New +$120K ﹤0.01% 11023
2024
Q2 		– Sell
-22,389
Closed -$30.9K – 12162
2024
Q1 		$30.9K Buy
+22,389
New +$25.2K ﹤0.01% 11708
2023
Q2 		– Sell
-24,599
Closed -$13.8K – 12185
2023
Q1 		$13.8K Buy
+24,599
New +$18.6K ﹤0.01% 12141
2022
Q4 		– Sell
-14,137
Closed -$16K – 12555
2022
Q3 		$16K Buy
+14,137
New +$25.4K ﹤0.01% 12666

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group's CNTX Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Context Therapeutics (CNTX) in Q1 2026: 1,093,894 shares worth $2.87M. The stake represents ﹤0.01% of the portfolio and ranks #5358 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CNTX as recently as Q3 2025.

Susquehanna International Group first reported a position in CNTX in Q3 2022 and has held it in 7 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Susquehanna International Group held 1,093,894 shares of Context Therapeutics worth $2.87M as of Q1 2026.
  • Context Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Context Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5358 holding.
  • Susquehanna International Group first reported a position in Context Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.